



WU Li

Senior Partner



Areas of Practice

Dr. Li Wu is qualified as attorney at law and patent attorney in both China and the United States. His practices cover all aspects of intellectual property laws. He mainly focuses on providing a full spectrum of patent law services to the clients in a wide range of technical fields, especially the clients from the pharmaceutical and life science sectors, which include patent prosecutions, invalidations and litigations. Additionally, he is also very experienced in assisting the clients to set up their IP protection and enforcement strategies globally, particularly concerning their complex and advanced technologies, and regularly advises clients in IP matters in connection with their technology transferring and licensing.

Dr. Wu had worked in leading IP firms in both China and the United States, serving variety of clients ranging from startup companies to MNCs. He had also served as an in-house counsel in a multinational pharmaceutical company. Before starting his legal career, Dr. Wu had worked as a scientist in the field of neuroscience for more than 10 years and had published his research work in the world-famous scientific magazine Nature (Vol. 419:947-952).

Representative Matters

- Represents Amgen in a series of drug patent linkage actions against generic companies before Beijing IP Court and the CNIPA.
- Represented SHARP in the case OPPO vs. SHARP in the FRAND rate disputes concerning 4G LTE SEPs before the Shenzhen Intermediate Court.
- Represented AstraZeneca in defending its pharmaceutical compound patent concerning its blockbuster drug Ticagrelor before the Beijing High Court and successfully overturned the invalidation decision made by the Patent Re-examination Board; represent AstraZeneca in the retrial case concerning this patent raised by the Patent Re-examination Board.
- Represented AstraZeneca in a series of patent validity litigations and infringement litigations concerning its blockbuster drug Ticagrelor.



- Represented Edan, a public Chinese medical device company, in a series of infringement litigations and trade secret misappropriation cases brought up by the giant medical device company Mindray and successfully settled the cases for the client.
- Represented Nichia Corporation in a series of patent litigations against a Taiwan company Everlight Electronic before the Beijing IP Court and the Patent Re-examination Board and successfully won a completed victory for the client, and these litigations are part of a global patent war between these two LED giants in the world.
- Represented SINOPEC in a series of trade secret and patent disputes against INEOs that claimed damages over one billion RMB in total and successfully helped the client achieve a settlement.
- Represented Japanese TRP company in a series of patent validity litigations and patent infringement litigations concerning its key cylinder liner patents before the Patent Re-examination Board, Beijing IP Court and Beijing Supreme People's Court and won satisfactory results for the client.
- Represented high tech start-ups, public companies, multinational giants, as well as research institutions, including Sinopec, Novartis, Toyota, Yazaki, Nihon Kohden, Align Technology, Nichia, Michigan University, UCSF, Chinese Academy of Science, Qinghua University, Nanjing University, in patent prosecution and re-examination matters in the fields of pharmaceuticals, life sciences, medical devices, chemical engineering, mechanics and electronic engineers, and successfully obtained and protected hundreds of patents in these fields.

Awards

- Recommended IP Lawyer, Chambers Greater China Region Guide (2023, 2024)
- Recommended IP Lawyer, Chambers Asia-Pacific Guide (2021, 2022)
- Top 15 IP lawyers, ALB China (2019)
- Recommended IP Lawyer in China, Legal 500 (2019)

Publications/Speeches

- "China begins issuing anti-suit injunctions in SEP cases", Managing IP, December, 2020



- "Data supplementation for chemical and biotech patents in China", Chinese Business Law Journal, June 2018
- "China to establish its own drug patent linkage", Chinese Business Law Journal, November 2017
- "Coming to terms with the US introduction of DTSA", Chinese Business Law Journal, October, 2016
- "Fourth amendment to Patent Law aims to increase damages and more", Chinese Business Law Journal, May, 2015
- "SIPO Clarifies Its Sufficient Disclosure Requirement", Managing IP, February 2014
- "Foreign enterprises should study China's utility model patent regime", Chinese Business Law Journal, December, 2013
- "DNA patentability in China", Symposium of the SIPO/US Bar Liaison Council with China's State Intellectual Property Office (SIPO) and the All China Patent Attorney Association (ACPAA), June 3, 2013 at Cardozo School of Law, New York, USA.

Education

- J.D., Columbia Law School
- Ph.D. in Neuroscience, Columbia University
- M.S. in Neuroscience, Chinese Academy of Sciences
- B.S. in Biology, Nanjing University

Qualifications

- Licensed Lawyer (China and the State of Massachusetts)
- Licensed Patent Attorney (China and US)

Working Languages

- Mandarin Chinese
- English